SCHEMBL5175967

SCHEMBL5175967

O=Cc1cc(Oc2ccc(Cl)cc2)ccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SOS1 Q07889 2/20 0.44
▸ MAOA P21397 2/20 0.42
▸ MAOB P27338 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ AR P10275 1/20 0.40
▸ ERN1 O75460 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24512757 0.88 TDP1 (0.44) SOS1MAOAMAOBTDP1AR
SCHEMBL31556425 0.86 LMNA (0.50) SOS1MAOAMAOBERN1FFAR4
SCHEMBL2536648 0.86 LMNA (0.50) SOS1MAOAMAOBERN1FFAR4
SCHEMBL15809138 0.80 TDP1 (0.62) SOS1MAOAMAOBTDP1ERN1
SCHEMBL11288471 0.79 FFAR4 (0.43) MAOAMAOBERN1FFAR4NFE2L2
SCHEMBL27720125 0.79 HSPB1 (0.58) ERN1POLBMEN1KMT2ANPSR1
SCHEMBL29958016 0.78 ERN1 (0.59) TDP1ERN1HSD17B10MEN1KMT2A
SCHEMBL42333 0.78 ERN1 (0.59) TDP1ERN1HSD17B10MEN1KMT2A
SCHEMBL18957581 0.77 MAOA (0.46) MAOAMAOBTDP1ERN1SMN1; SMN2
SCHEMBL15904234 0.77 ERN1 (0.46) TDP1ERN1SMN1; SMN2POLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173434-A1 Antidiabetic oxazolidinediones and thiazolidinediones MERCK SHARP & DOHME CORP. 2007-07-26 — — US disclosed
US-20070173434-A1 Antidiabetic oxazolidinediones and thiazolidinediones MERCK SHARP & DOHME CORP. 2007-07-26 — — US disclosed
US-20070173434-A1 Antidiabetic oxazolidinediones and thiazolidinediones MERCK SHARP & DOHME CORP. 2007-07-26 — — US disclosed
EP-1709014-B1 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES MERCK & CO INC (US) 2007-05-30 — — EP disclosed
EP-1709014-B1 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES MERCK & CO INC (US) 2007-05-30 — — EP disclosed
EP-1709014-A1 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES Merck & Co., Inc. (US) 2006-10-11 — — EP disclosed
WO-2005070905-A1 ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES MERCK & CO., INC. (US) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173434-A1 Antidiabetic oxazolidinediones and thiazolidinediones PPARD, PPARA, PPARG SOS1 3368/4885MAOA 3756/4885MAOB 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback